Efficacy and Toxicity Associated with Cancer Drug Approvals in Switzerland: International Implications

The Lancet Regional Health. Europe · Published 2026-06-18 · DOI 10.1016/j.lanepe.2026.101748

Free full text

Authors (3)

Ariadna Tibau, Aaron S. Kesselheim, Thomas J. Hwang

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Citation

Tibau, A., Kesselheim, A., Hwang, T. (2026). Efficacy and Toxicity Associated with Cancer Drug Approvals in Switzerland: International Implications. The Lancet Regional Health. Europe. https://doi.org/10.1016/j.lanepe.2026.101748

Related articles

• Estimating the Potential Burden of Clinically Significant Hantavirus Cases in Argentina · The Lancet Regional Health. Europe · 2026 · Same journal
• GLP-1 receptor agonists in type 1 diabetes: expanding the therapeutic landscape beyond insulin · The Lancet Regional Health. Europe · 2026 · Same journal
• Closing the Implementation Gap: New Models of Care to End Chronic Liver Disease · The Lancet Regional Health. Europe · 2026 · Same journal
• Ending the Chronic Liver Disease Public Health Threat: Systemic Challenges Through the Patient Lens · The Lancet Regional Health. Europe · 2026 · Same journal
• Preparing Europe for Recurrent Autochthonous Dengue Transmission: Public Health Implications and Preparedness Priorities · The Lancet Regional Health. Europe · 2026 · Same journal
• From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid Therapy · The Lancet Regional Health. Europe · 2026 · Same journal
• Nordic AI-Health: a unique opportunity for discovery and clinical impact · The Lancet Regional Health. Europe · 2026 · Same journal
• Safety of the Dengue Vaccine TAK-003 and Factors Associated with Adverse Events in Travellers from Non-Endemic Areas: A Real-World Prospective Multicentre Pharmacovigilance Cohort Study in Spain · The Lancet Regional Health. Europe · 2026 · Same journal
• Assessing Europe's policy readiness to confront the MASLD/MASH public health threat · The Lancet Regional Health. Europe · 2026 · Same journal
• Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension · The Lancet Regional Health. Europe · 2026 · Same journal